Ra Pharmaceuticals, Inc. Insider Trading for October 2016
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Ra Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Ra Pharmaceuticals, Inc. for October 2016.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | C | 0.00 | 4,015,378 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Option Exercise | C | 0.00 | 4,316,531 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | P | 13.00 | 161,538 | 2,099,994 | 1,351,808 | 1.2 M to 1.4 M (+13.57 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | C | 0.00 | 573,624 | 0 | 1,190,270 | 616.6 K to 1.2 M (+93.02 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, LLC | Director | Buy | C | 0.00 | 616,646 | 0 | 616,646 | 0 to 616.6 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Shah Rajeev M. | Director | Option Exercise | C | 0.00 | 4,015,378 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Shah Rajeev M. | Director | Option Exercise | C | 0.00 | 4,316,531 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Shah Rajeev M. | Director | Buy | P | 13.00 | 161,538 | 2,099,994 | 1,351,808 | 1.2 M to 1.4 M (+13.57 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Shah Rajeev M. | Director | Buy | C | 0.00 | 573,624 | 0 | 1,190,270 | 616.6 K to 1.2 M (+93.02 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Shah Rajeev M. | Director | Buy | C | 0.00 | 616,646 | 0 | 616,646 | 0 to 616.6 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | EVP & CFO | Option Exercise | A | 2.87 | 29,285 | 84,048 | 29,285 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Weller Harry R | 10% Owner | Option Exercise | C | 0.00 | 4,362,472 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Weller Harry R | 10% Owner | Option Exercise | C | 0.00 | 4,689,657 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Weller Harry R | 10% Owner | Option Exercise | C | 0.00 | 12,447,605 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Weller Harry R | 10% Owner | Option Exercise | X | 0.07 | 80,658 | 5,646 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Weller Harry R | 10% Owner | Buy | P | 13.00 | 338,462 | 4,400,006 | 3,490,073 | 3.2 M to 3.5 M (+10.74 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Weller Harry R | 10% Owner | Buy | C | 0.00 | 623,210 | 0 | 3,151,611 | 2.5 M to 3.2 M (+24.65 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Weller Harry R | 10% Owner | Buy | C | 0.00 | 669,951 | 0 | 2,528,401 | 1.9 M to 2.5 M (+36.05 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Weller Harry R | 10% Owner | Buy | C | 0.00 | 1,778,227 | 0 | 1,858,450 | 80.2 K to 1.9 M (+2,216.60 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Weller Harry R | 10% Owner | Sell | S | 13.00 | 435 | 5,655 | 80,223 | 80.7 K to 80.2 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Weller Harry R | 10% Owner | Buy | X | 0.07 | 80,658 | 5,646 | 80,658 | 0 to 80.7 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MORGENTHALER VENTURE PARTNERS ... | 10% Owner | Option Exercise | C | 0.00 | 3,408,439 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MORGENTHALER VENTURE PARTNERS ... | 10% Owner | Option Exercise | C | 0.00 | 3,664,071 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MORGENTHALER VENTURE PARTNERS ... | 10% Owner | Option Exercise | C | 0.00 | 9,744,916 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MORGENTHALER VENTURE PARTNERS ... | 10% Owner | Option Exercise | X | 0.07 | 63,019 | 4,411 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MORGENTHALER VENTURE PARTNERS ... | 10% Owner | Buy | P | 13.00 | 263,538 | 3,425,994 | 2,745,846 | 2.5 M to 2.7 M (+10.62 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MORGENTHALER VENTURE PARTNERS ... | 10% Owner | Buy | C | 0.00 | 486,919 | 0 | 2,482,308 | 2 M to 2.5 M (+24.40 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MORGENTHALER VENTURE PARTNERS ... | 10% Owner | Buy | C | 0.00 | 523,438 | 0 | 1,995,389 | 1.5 M to 2 M (+35.56 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MORGENTHALER VENTURE PARTNERS ... | 10% Owner | Buy | C | 0.00 | 1,392,130 | 0 | 1,471,951 | 79.8 K to 1.5 M (+1,744.06 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MORGENTHALER VENTURE PARTNERS ... | 10% Owner | Sell | S | 13.00 | 340 | 4,420 | 79,821 | 80.2 K to 79.8 K (-0.42 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MORGENTHALER VENTURE PARTNERS ... | 10% Owner | Buy | X | 0.07 | 63,019 | 4,411 | 80,161 | 17.1 K to 80.2 K (+367.63 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Viswanathan Ravi | 10% Owner | Option Exercise | C | 0.00 | 4,362,472 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Viswanathan Ravi | 10% Owner | Option Exercise | C | 0.00 | 4,689,657 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Viswanathan Ravi | 10% Owner | Option Exercise | C | 0.00 | 12,447,605 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Viswanathan Ravi | 10% Owner | Option Exercise | X | 0.07 | 80,658 | 5,646 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Viswanathan Ravi | 10% Owner | Buy | P | 13.00 | 338,462 | 4,400,006 | 3,490,073 | 3.2 M to 3.5 M (+10.74 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Viswanathan Ravi | 10% Owner | Buy | C | 0.00 | 623,210 | 0 | 3,151,611 | 2.5 M to 3.2 M (+24.65 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Viswanathan Ravi | 10% Owner | Buy | C | 0.00 | 669,951 | 0 | 2,528,401 | 1.9 M to 2.5 M (+36.05 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Viswanathan Ravi | 10% Owner | Buy | C | 0.00 | 1,778,227 | 0 | 1,858,450 | 80.2 K to 1.9 M (+2,216.60 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Viswanathan Ravi | 10% Owner | Sell | S | 13.00 | 435 | 5,655 | 80,223 | 80.7 K to 80.2 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Viswanathan Ravi | 10% Owner | Buy | X | 0.07 | 80,658 | 5,646 | 80,658 | 0 to 80.7 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | SANDELL SCOTT D | 10% Owner | Option Exercise | C | 0.00 | 4,362,472 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | SANDELL SCOTT D | 10% Owner | Option Exercise | C | 0.00 | 4,689,657 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | SANDELL SCOTT D | 10% Owner | Option Exercise | C | 0.00 | 12,447,605 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | SANDELL SCOTT D | 10% Owner | Option Exercise | X | 0.07 | 80,658 | 5,646 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | SANDELL SCOTT D | 10% Owner | Buy | P | 13.00 | 338,462 | 4,400,006 | 3,490,073 | 3.2 M to 3.5 M (+10.74 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | SANDELL SCOTT D | 10% Owner | Buy | C | 0.00 | 623,210 | 0 | 3,151,611 | 2.5 M to 3.2 M (+24.65 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | SANDELL SCOTT D | 10% Owner | Buy | C | 0.00 | 669,951 | 0 | 2,528,401 | 1.9 M to 2.5 M (+36.05 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | SANDELL SCOTT D | 10% Owner | Buy | C | 0.00 | 1,778,227 | 0 | 1,858,450 | 80.2 K to 1.9 M (+2,216.60 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | SANDELL SCOTT D | 10% Owner | Sell | S | 13.00 | 435 | 5,655 | 80,223 | 80.7 K to 80.2 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | SANDELL SCOTT D | 10% Owner | Buy | X | 0.07 | 80,658 | 5,646 | 80,658 | 0 to 80.7 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 481,503 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 3,533,875 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 517,617 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 3,798,914 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 3,408,439 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 3,664,071 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 9,744,916 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | X | 0.07 | 63,019 | 4,411 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | P | 13.00 | 15,633 | 203,229 | 4,066,503 | 4.1 M to 4.1 M (+0.39 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | P | 13.00 | 114,752 | 1,491,776 | 4,050,870 | 3.9 M to 4.1 M (+2.92 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | P | 13.00 | 263,538 | 3,425,994 | 3,936,118 | 3.7 M to 3.9 M (+7.18 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 68,786 | 0 | 3,672,580 | 3.6 M to 3.7 M (+1.91 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 504,839 | 0 | 3,603,794 | 3.1 M to 3.6 M (+16.29 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 73,945 | 0 | 3,098,955 | 3 M to 3.1 M (+2.44 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 542,702 | 0 | 3,025,010 | 2.5 M to 3 M (+21.86 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 486,919 | 0 | 2,482,308 | 2 M to 2.5 M (+24.40 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 523,438 | 0 | 1,995,389 | 1.5 M to 2 M (+35.56 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 1,392,130 | 0 | 1,471,951 | 79.8 K to 1.5 M (+1,744.06 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Sell | S | 13.00 | 340 | 4,420 | 79,821 | 80.2 K to 79.8 K (-0.42 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | X | 0.07 | 63,019 | 4,411 | 80,161 | 17.1 K to 80.2 K (+367.63 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 4,362,472 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 4,689,657 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 12,447,605 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MOTT DAVID M | 10% Owner | Option Exercise | X | 0.07 | 80,658 | 5,646 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MOTT DAVID M | 10% Owner | Buy | P | 13.00 | 338,462 | 4,400,006 | 3,490,073 | 3.2 M to 3.5 M (+10.74 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 623,210 | 0 | 3,151,611 | 2.5 M to 3.2 M (+24.65 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 669,951 | 0 | 2,528,401 | 1.9 M to 2.5 M (+36.05 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 1,778,227 | 0 | 1,858,450 | 80.2 K to 1.9 M (+2,216.60 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MOTT DAVID M | 10% Owner | Sell | S | 13.00 | 435 | 5,655 | 80,223 | 80.7 K to 80.2 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | MOTT DAVID M | 10% Owner | Buy | X | 0.07 | 80,658 | 5,646 | 80,658 | 0 to 80.7 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KOLLURI KRISHNA KITTU | 10% Owner | Option Exercise | C | 0.00 | 4,362,472 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KOLLURI KRISHNA KITTU | 10% Owner | Option Exercise | C | 0.00 | 4,689,657 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KOLLURI KRISHNA KITTU | 10% Owner | Option Exercise | C | 0.00 | 12,447,605 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KOLLURI KRISHNA KITTU | 10% Owner | Option Exercise | X | 0.07 | 80,658 | 5,646 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KOLLURI KRISHNA KITTU | 10% Owner | Buy | P | 13.00 | 338,462 | 4,400,006 | 3,490,073 | 3.2 M to 3.5 M (+10.74 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KOLLURI KRISHNA KITTU | 10% Owner | Buy | C | 0.00 | 623,210 | 0 | 3,151,611 | 2.5 M to 3.2 M (+24.65 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KOLLURI KRISHNA KITTU | 10% Owner | Buy | C | 0.00 | 669,951 | 0 | 2,528,401 | 1.9 M to 2.5 M (+36.05 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KOLLURI KRISHNA KITTU | 10% Owner | Buy | C | 0.00 | 1,778,227 | 0 | 1,858,450 | 80.2 K to 1.9 M (+2,216.60 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KOLLURI KRISHNA KITTU | 10% Owner | Sell | S | 13.00 | 435 | 5,655 | 80,223 | 80.7 K to 80.2 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KOLLURI KRISHNA KITTU | 10% Owner | Buy | X | 0.07 | 80,658 | 5,646 | 80,658 | 0 to 80.7 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 3,402,729 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 3,657,932 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 9,728,589 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | X | 0.07 | 62,914 | 4,404 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Buy | P | 13.00 | 84,615 | 1,099,995 | 2,545,652 | 2.5 M to 2.5 M (+3.44 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 486,104 | 0 | 2,461,037 | 2 M to 2.5 M (+24.61 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 522,561 | 0 | 1,974,933 | 1.5 M to 2 M (+35.98 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 1,389,797 | 0 | 1,452,372 | 62.6 K to 1.5 M (+2,221.01 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 13.00 | 339 | 4,407 | 62,575 | 62.9 K to 62.6 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Buy | X | 0.07 | 62,914 | 4,404 | 62,914 | 0 to 62.9 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KERINS PATRICK J | 10% Owner | Option Exercise | C | 0.00 | 4,362,472 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KERINS PATRICK J | 10% Owner | Option Exercise | C | 0.00 | 4,689,657 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KERINS PATRICK J | 10% Owner | Option Exercise | C | 0.00 | 12,447,605 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KERINS PATRICK J | 10% Owner | Option Exercise | X | 0.07 | 80,658 | 5,646 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KERINS PATRICK J | 10% Owner | Buy | P | 13.00 | 338,462 | 4,400,006 | 3,490,073 | 3.2 M to 3.5 M (+10.74 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KERINS PATRICK J | 10% Owner | Buy | C | 0.00 | 623,210 | 0 | 3,151,611 | 2.5 M to 3.2 M (+24.65 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KERINS PATRICK J | 10% Owner | Buy | C | 0.00 | 669,951 | 0 | 2,528,401 | 1.9 M to 2.5 M (+36.05 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KERINS PATRICK J | 10% Owner | Buy | C | 0.00 | 1,778,227 | 0 | 1,858,450 | 80.2 K to 1.9 M (+2,216.60 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KERINS PATRICK J | 10% Owner | Sell | S | 13.00 | 435 | 5,655 | 80,223 | 80.7 K to 80.2 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | KERINS PATRICK J | 10% Owner | Buy | X | 0.07 | 80,658 | 5,646 | 80,658 | 0 to 80.7 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BASKETT FOREST | 10% Owner | Option Exercise | C | 0.00 | 4,362,472 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BASKETT FOREST | 10% Owner | Option Exercise | C | 0.00 | 4,689,657 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BASKETT FOREST | 10% Owner | Option Exercise | C | 0.00 | 12,447,605 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BASKETT FOREST | 10% Owner | Option Exercise | X | 0.07 | 80,658 | 5,646 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BASKETT FOREST | 10% Owner | Buy | P | 13.00 | 338,462 | 4,400,006 | 3,490,073 | 3.2 M to 3.5 M (+10.74 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BASKETT FOREST | 10% Owner | Buy | C | 0.00 | 623,210 | 0 | 3,151,611 | 2.5 M to 3.2 M (+24.65 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BASKETT FOREST | 10% Owner | Buy | C | 0.00 | 669,951 | 0 | 2,528,401 | 1.9 M to 2.5 M (+36.05 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BASKETT FOREST | 10% Owner | Buy | C | 0.00 | 1,778,227 | 0 | 1,858,450 | 80.2 K to 1.9 M (+2,216.60 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BASKETT FOREST | 10% Owner | Sell | S | 13.00 | 435 | 5,655 | 80,223 | 80.7 K to 80.2 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BASKETT FOREST | 10% Owner | Buy | X | 0.07 | 80,658 | 5,646 | 80,658 | 0 to 80.7 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRIS PETER J | 10% Owner | Option Exercise | C | 0.00 | 4,362,472 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRIS PETER J | 10% Owner | Option Exercise | C | 0.00 | 4,689,657 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRIS PETER J | 10% Owner | Option Exercise | C | 0.00 | 12,447,605 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRIS PETER J | 10% Owner | Option Exercise | X | 0.07 | 80,658 | 5,646 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRIS PETER J | 10% Owner | Buy | P | 13.00 | 338,462 | 4,400,006 | 3,490,073 | 3.2 M to 3.5 M (+10.74 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRIS PETER J | 10% Owner | Buy | C | 0.00 | 623,210 | 0 | 3,151,611 | 2.5 M to 3.2 M (+24.65 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRIS PETER J | 10% Owner | Buy | C | 0.00 | 669,951 | 0 | 2,528,401 | 1.9 M to 2.5 M (+36.05 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRIS PETER J | 10% Owner | Buy | C | 0.00 | 1,778,227 | 0 | 1,858,450 | 80.2 K to 1.9 M (+2,216.60 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRIS PETER J | 10% Owner | Sell | S | 13.00 | 435 | 5,655 | 80,223 | 80.7 K to 80.2 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRIS PETER J | 10% Owner | Buy | X | 0.07 | 80,658 | 5,646 | 80,658 | 0 to 80.7 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRETT M JAMES | 10% Owner | Option Exercise | C | 0.00 | 4,362,472 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRETT M JAMES | 10% Owner | Option Exercise | C | 0.00 | 4,689,657 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRETT M JAMES | 10% Owner | Option Exercise | C | 0.00 | 12,447,605 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRETT M JAMES | 10% Owner | Option Exercise | X | 0.07 | 80,658 | 5,646 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRETT M JAMES | 10% Owner | Buy | P | 13.00 | 338,462 | 4,400,006 | 3,490,073 | 3.2 M to 3.5 M (+10.74 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRETT M JAMES | 10% Owner | Buy | C | 0.00 | 623,210 | 0 | 3,151,611 | 2.5 M to 3.2 M (+24.65 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRETT M JAMES | 10% Owner | Buy | C | 0.00 | 669,951 | 0 | 2,528,401 | 1.9 M to 2.5 M (+36.05 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRETT M JAMES | 10% Owner | Buy | C | 0.00 | 1,778,227 | 0 | 1,858,450 | 80.2 K to 1.9 M (+2,216.60 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRETT M JAMES | 10% Owner | Sell | S | 13.00 | 435 | 5,655 | 80,223 | 80.7 K to 80.2 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | BARRETT M JAMES | 10% Owner | Buy | X | 0.07 | 80,658 | 5,646 | 80,658 | 0 to 80.7 K |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | C | 0.00 | 4,362,472 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | C | 0.00 | 4,689,657 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | C | 0.00 | 12,447,605 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | X | 0.07 | 80,658 | 5,646 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Buy | P | 13.00 | 338,462 | 4,400,006 | 3,490,073 | 3.2 M to 3.5 M (+10.74 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Buy | C | 0.00 | 623,210 | 0 | 3,151,611 | 2.5 M to 3.2 M (+24.65 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Buy | C | 0.00 | 669,951 | 0 | 2,528,401 | 1.9 M to 2.5 M (+36.05 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Buy | C | 0.00 | 1,778,227 | 0 | 1,858,450 | 80.2 K to 1.9 M (+2,216.60 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Sell | S | 13.00 | 435 | 5,655 | 80,223 | 80.7 K to 80.2 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Buy | X | 0.07 | 80,658 | 5,646 | 80,658 | 0 to 80.7 K |